Robin Davison, Proactive Research analyst, talks to Katie about Poolbeg Pharma commencing its Phase 1 human challenge trial for its lead molecule POLB 001, for the treatment of severe influenza.
The company has received ethics and competent authority approval for the study and expects to carry out the site initiation visit later this week, which will be a year since the pharma firm listed in London.